Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMI and Safety of Qdenga in Children
NCT02948829Phase 2Completed
- Sponsor
- Takeda
- Start
- Apr 2017
- Primary completion
- Oct 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of dengue tetravalent vaccine (live, attenuated) in dengue fever, sponsored by Takeda. Primary endpoint: Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV). Started Apr 2017; status: completed.
02
Drugs
dengue tetravalent vaccine (live, attenuated)
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02948829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02948829.